Business Wire

INNIO

23.6.2022 10:32:13 CEST | Business Wire | Press release

Share
INNIO publishes Sustainability Report for 2021, setting ambitious targets on the path to net zero

INNIO, a leading energy solution and service provider, has published its Sustainability Report for 2021 Together Towards Zero , which defines the company’s performance in meeting environmental, social, and governance (ESG) goals. While INNIO is currently empowering industries and communities to transition to net zero, this report – prepared in accordance with GRI and SASB standards – formally communicates on progress and sustainability-related performance providing, transparency about how INNIO is contributing to a green tomorrow.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005974/en/

Earlier this year, Sustainalytics ranked INNIO number one out more than 500 companies, meaning it has the lowest risk within the machinery industry assessed (Rating of 11 “Low risk level”). In addition, INNIO received the Gold Medal from EcoVadis, placing its Jenbacher business in the top 1% of industry peers. Last year, INNIO became signatory of the Science Based Targets initiative and the United Nations ‘Race to Zero’ campaign, that brings together global leadership for a healthy, resilient, and zero-carbon future.

In accordance with global frameworks and commitments, INNIO set out ambitious sustainability targets in three strategic focus areas where it sees the most material impacts and opportunities for improvement: Low Carbon and Circular Products , Resilient Supply Chain and Manufacturing , and Responsible Operations and Social Responsibility .

Selected key ambitions in these areas include:

  • Since 2022, INNIO offers all new engines with a “Ready for H2” option. These models can operate with up to 20% vol. hydrogen1 , and can be retrofitted to 100% H2 operation in the future. All Type 4 series engines are offered for 100% H2 operations. As of 2025 and beyond, the entire Jenbacher product line is expected to be rolled out with 100% hydrogen operation.
  • Suppliers covering 80% of direct and indirect spend must commit to net zero by 2050.
  • 50% reduction in Scope 1 and Scope 2 GHG emissions in supply chain and manufacturing (vs. the 2020 base) will be fully implemented by 2030.
  • By 2025, identified diversity groups will increase by 25% across functions compared to the 2020 baseline. Diverse people leadership will be developed further by 20302 .

Dr. Olaf Berlien, chief executive officer at INNIO, states:

“I’m incredibly proud of the steps we have taken to implement our ESG strategy. The outstanding recognition we have received for our achievements with leading ESG ratings shows that we are on the right track on our path to net zero.”

Marcin Kawa, vice president Sustainability at INNIO, states:

“INNIO’s 2021 Sustainability Report summarizes a year filled with sustainability and ESG initiatives, collaboration, and progress. “This report is the next milestone in our journey as we move ‘Together Towards Zero.’ I’m happy to be part of a team that is so passionate about making a difference while building transparency and trust among our stakeholders worldwide.”

* Rating took place in February 2022

About INNIO’s 2021 Sustainability Report

INNIO’s 2021 Sustainability Report is a non-financial disclosure published annually. This 2021 disclosure was prepared in accordance with the standards of the Global Reporting Initiative (GRI) core option and the Sustainability Accounting Standards Board (SASB). It also includes an initial analysis in line with the Task Force on Climate-related Financial Disclosures (TCFD) Recommendations Framework. The report also serves as Communication on Progress (COP) for the UN Global Compact (UNGC). Through non-financial reporting, INNIO describes its management and performance of environmental, social, and governance (ESG) issues. INNIO’s disclosures focus on the topics that have been deemed most material to the business based on a materiality assessment. INNIO’s alignment with the United Nations Sustainable Development Goals (UN SDGs) is based on the GRI and the UNGC’s Business Reporting on the UN SDGs. This Sustainability Report has been externally assured. The data presented in the report is consolidated at Group level and covers 100% of business operations and 90% of global locations. This boundary applies to all material topics, unless clearly indicated otherwise. All the health, safety, and environmental data, including greenhouse gas (GHG) data for Scope 1, Scope 2, and Scope 3, cover the INNIO Group using the financial control approach.

For more information, access INNIO’s Sustainability Report 2021 here .

About INNIO

INNIO is a leading energy solution and service provider that empowers industries and communities to make sustainable energy work today. With our product brands Jenbacher and Waukesha and our digital platform myPlant, INNIO offers innovative solutions for the power generation and compression segments that help industries and communities generate and manage energy sustainably while navigating the fast-changing landscape of traditional and green energy sources. We are individual in scope, but global in scale. With our flexible, scalable, and resilient energy solutions and services, we are enabling our customers to manage the energy transition along the energy value chain wherever they are in their transition journey.

INNIO is headquartered in Jenbach (Austria), with other primary operations in Waukesha (Wisconsin, U.S.) and Welland (Ontario, Canada). A team of more than 3,500 experts provides life-cycle support to the more than 54,000 delivered engines globally through a service network in more than 80 countries.

INNIO’s ESG Risk Rating places it number one of more than 500 worldwide companies in the Machinery industry assessed by Sustainalytics.

For more information, visit INNIO’s website at www.innio.com . Follow INNIO on Twitter and LinkedIn .

1 Defined in accounting protocol as either sold with the capacity to run on 100% hydrogen or that can be upgraded at a reasonable cost
2 We will focus on distinct employee groups and diversity dimensions (age, gender, nationality, and minorities) when implementing diversity initiatives. For more information, please visit page 78 in our report.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye